Premium
Mechanism of penehyclidine hydrochloride on a dysmenorrhea rat model
Author(s) -
Xiao Hongtao,
Shi Tingting,
Han Lizhu,
Tong Rongsheng,
Liao Zhi
Publication year - 2019
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21500
Subject(s) - estradiol benzoate , h&e stain , medicine , uterus , western blot , pharmacology , receptor , endocrinology , hydrochloride , estrogen , chemistry , ovariectomized rat , immunohistochemistry , biochemistry , gene
Primary dysmenorrhea affects the quality of life in young women, particularly school and work performance. This study investigated the mechanisms of penehyclidine hydrochloride (PHC) efficacy on a rat model of primary dysmenorrhea. The model was induced by injecting both estradiol benzoate and oxytocin. Different doses of PHC were administrated intraperitoneally following estradiol benzoate administration. Writhing scores were assessed, and pathological changes of the uterus were observed via hematoxylin and eosin staining. Western blot and real‐time PCR were used to evaluate the expression level of the M 3 receptor, both TLR 3 and TLR 4 in uterine tissue, and the level of Ca 2+ was measured in uterine tissues. Writhing scores significantly decreased in the PHC treatment group compared to model, and PHC alleviated the occurrence of edema or necrosis in the uteri compared to model group. PHC can decrease the M 3 receptor, TLR 3 , TLR 4 expression, and the Ca 2+ level compared to the model group. PHC is a potential candidate for the future treatment of primary dysmenorrhea due to its ability to attenuate muscarinic receptors and TLRs.Preclinical Research & Development